Login / Signup

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.

Jose Luis CallejaJesus Manuel Rivera EstebanRocío AllerMarta Hernández-CondeJavier AbadJuan Manuel PericàsHugo G BenitoMiguel A SerraAmparo EscuderoJavier AmpueroAna LucenaYolanda SánchezMaria Teresa Arias-LostePaula IruzubietaManuel RomeroSalvador AugustinJavier Crespo
Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)
These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.
Keyphrases
  • risk factors
  • liver fibrosis
  • quality improvement
  • cerebral ischemia
  • mass spectrometry
  • drug induced